Feldan Therapeutics announced that it has raised $16.5 million in a round of funding on June 13, 2023. The transaction included participation from new investors Investissement Québec, Investment Arm, Amgen Ventures, and existing investor Green Cross Holdings Corporation and other existing shareholders. Green Cross Holdings Corporation was supported by GC Cell (South Korea) and FSIT2.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16,050 KRW | +2.49% | +2.16% | -1.83% |
Mar. 20 | Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Tiantan Biological Unit Registers Blood Disorder Treatment; Shares Jump 4% | MT |
1st Jan change | Capi. | |
---|---|---|
-1.83% | 528M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- A005250 Stock
- News Green Cross Holdings Corporation
- Feldan Therapeutics announced that it has received $16.5 million in funding from Amgen Ventures, Investissement Québec, Investment Arm, Green Cross Holdings Corporation and other investors